Clinical and radiological features of osteonecrosis in systemic lupus erythematosus

I. D. GRIFFITHS, R. N. MAINI, AND J. T. SCOTT

From the Kennedy Institute of Rheumatology, London

SUMMARY Symptomatic osteonecrosis occurred in 8 out of 68 patients with systemic lupus erythematosus. Multiple joints were involved in 3 patients, and weight-bearing joints were most frequently affected. Osteonecrosis tended to occur early in the disease, and the patients had all received corticosteroids. Symptoms tended to occur when the disease had progressed from an active phase into one of clinical and serological quiescence. In weight-bearing joints classical radiological changes were often absent at the onset of symptoms.

The survival rates of patients with systemic lupus erythematosus (SLE) have improved considerably in the past 20 years (Dubois, 1976) and this is mainly due to better therapy and the recognition of milder forms of the disease. However, with the increased life expectancy of SLE patients complications which may produce marked functional impairment, such as avascular necrosis or osteonecrosis, become increasingly important in the long-term management of these patients. In this paper we have preferred to use the term osteonecrosis instead of avascular necrosis of bone because we feel that the latter term implies a pathogenic mechanism which has not yet been clearly demonstrated in SLE (Jones, 1978).

Osteonecrosis was first described in SLE patients by Dubois and Cozens (1960), and subsequent reviews have reported incidences varying from 5% to 40% (Bergstein et al., 1974; Dubois, 1976). We have retrospectively reviewed the incidence, clinical features, therapy, and serological abnormalities in patients who have developed symptomatic osteonecrosis in the SLE population we have followed.

Patients and methods

Patients were reviewed who had had SLE for at least 2 years since the onset of first symptoms and who had been followed up in the clinic for at least 1 year. All patients had a minimum of 3 of the American Rheumatism Association (ARA) criteria for SLE (excluding LE cells) (Cohen et al., 1971) and either positive LE cells or antinuclear antibodies. All patients had standard x-rays of the hands, feet, and chest, and no patient had radiological evidence of joint erosion. Other joint radiographs were taken only if symptoms indicated. A total of 68 patients were reviewed.

The diagnosis of osteonecrosis was in all cases based on both the clinical picture of continuing joint pain in the absence of persistent synovitis and typical radiological changes. The radiological features which we considered to be indicative of osteonecrosis were based on the British Medical Research Council's recommendations (McCullum and Walder, 1966). All our patients had the juxta-articular type of lesion rather than the shaft lesions. The appearances varied from either localised lytic or increased density lesions within an intact articular cortex to structural failure of the articular cortex with subchondral fractures, or collapse of articular cartilage or reabsorption of bone. Many patients showed a progression of radiological changes.

Results

Eight out of the 68 patients developed symptomatic osteonecrosis. A total of 13 joints were involved, 3 of the patients having multiple joint involvement. The clinical features of the patients with and without osteonecrosis are compared in Table 1. No statistical difference in the incidence of any feature was observed between the 2 groups, but renal involvement was more common in the osteo-
necrosis group, and this may have had some bearing on therapy. Brief case histories of the patients with osteonecrosis are recorded below.

Case 1. A 52-year-old Canadian woman developed polyarthritis, pericarditis, alopecia, and oropharyngeal ulceration in December 1973. LE cells and ANA were positive. She was treated with prednisolone 100 mg daily. The dose was rapidly reduced, but in June 1974 she had an episode of pleurisy, which responded to 40 mg of prednisolone daily, gradually being reduced to 20 mg daily by October 1974. At this stage the patient was well apart from some pain in the left hip. There was no history of preceding trauma. Initial radiographs were normal, but pain in the left hip persisted, and a repeat radiograph in May 1975 showed what we take to be osteonecrosis of the left acetabular margin (Fig. 1).

The disease had otherwise remained inactive and she was receiving prednisolone 14 mg daily.

Case 2. A 30-year-old Englishwoman developed polyarthritis, oropharyngeal ulceration, and leucopenia in September 1970. ANA and LE cells were positive. She was treated with prednisolone 40 mg daily, gradually reducing to 10 mg daily. In December 1971 she started to complain of pain in the left hip, and radiographs 1 month, 5 months, and 11 months later showed changes of progressive osteonecrosis (Fig. 2). In May 1972 she complained of pain in the right hip, but x-rays of that joint were normal; the pain resolved after 3 weeks' bed rest.

The patient was maintained on prednisolone 10 mg daily. In November 1972 she developed a nephrotic syndrome progressing to renal failure, from which she died in February 1973.

Case 3. A 19-year-old Greek woman developed polyarthritis and lymphadenopathy in May 1973. In December 1973 treatment with prednisolone was started. In April 1974 she was found to have proteinuria with granular casts in the urine, and a renal biopsy showed an active diffuse, proliferative glomerulonephritis. She also developed recurrent episodes of pleurisy and psychosis. ANA and LE cells were positive, DNA binding >2000 units/ml, C3, C4, and CH50 values were all depressed. Haemoglobin electrophoresis was normal. She was treated with prednisolone 60 mg daily and azathioprine 3 mg/kg body weight, and the disease became inactive by May 1974. The prednisolone was gradually reduced to 20 mg daily, but she remained on

| Table 1 Clinical features of SLE patients with osteonecrosis compared to those without |
|---------------------|---------------------|
|                     | Patients with osteonecrosis | Patients without osteonecrosis |
| Total number        | 8                        | 60                        |
| Facial rash         | 3 (28%)                  | 29 (47%)                  |
| Discoid lupus       | 0                        | 3 (5%)                    |
| Raynaud's phenomenon| 4 (50%)                  | 31 (58%)                  |
| Alopecia            | 4 (50%)                  | 23 (39%)                  |
| Photosensitivity    | 1 (13%)                  | 11 (19%)                  |
| Oropharyngeal ulcers| 1 (13%)                  | 12 (22%)                  |
| Arthritis           | 8 (100%)                 | 55 (92%)                  |
| Pleuropericardial disease | 3 (38%)           | 22 (36%)                  |
| CNS involvement     | 1 (13%)                  | 15 (25%)                  |
| LE cells            | 7 (88%)                  | 50 (83%)                  |
| Proteinuria         | 4 (50%)                  | 17 (29%)                  |
| Haematological features | 3 (38%)              | 24 (39%)                  |

Fig. 1 Case 1. X-rays of left hip (a) 3 months and (b) 7 months after onset of symptoms
Clinical and radiological features of osteonecrosis in systemic lupus erythematosus

Fig. 2  Case 2. X-rays of left hip (a) 1 month, (b) 5 months, and (c) 11 months after onset of symptoms

Fig. 3  Case 3. Control X-ray of (a) right hip (IVP) and appearances (b) 9 months and (c) 1 year after onset of symptoms

Fig. 4  Case 5. X-rays of left hip (a) 6 months, (b) 9 months, and (c) 22 months after onset of symptoms
azathioprine. In May 1975, when the disease was quiescent both clinically and serologically, she started to complain of pain in the right hip, and radiographs in February 1976 revealed changes of osteonecrosis of the right femoral head, which progressed over the ensuing year in spite of prednisolone being reduced to 7 mg daily (Fig. 3).

Case 4. A 28-year-old Egyptian woman developed polyarthritis, lymphadenopathy, facial rash, and frontal alopecia in 1974. LE cells and ANA were positive. Haemoglobin electrophoresis was normal. Treatment with prednisolone 20 mg daily was started, and the dose was reduced to 10 mg daily by early 1976. However, during 1976 the C3, C4, and CH50 values fell, and DNA antibodies rose to >2000 units/ml. She became acutely ill in September 1976, with joint pains and fever, and progressed into coma with a grossly abnormal EEG and brain scan. The prednisolone was increased to 100 mg daily and cyclophosphamide given. The disease came into remission clinically and serologically by December 1976, and the prednisolone was reduced and the cyclophosphamide discontinued. She was discharged from hospital in December 1976 but shortly after discharge complained of pain in the right hip. An x-ray taken in June 1977 showed osteonecrosis of the right femoral head. At that time she was taking 19 mg of prednisolone daily.

Case 5. A 25-year-old West Indian woman presented with a polyarthritis, Raynaud's phenomenon, and leucopenia in March 1973. DAT (differential agglutination titre) and LE cells were negative but the ANA was positive. Haemoglobin electrophoresis was normal. In June 1973 she developed pleurisy and was treated with prednisolone 60 mg daily then gradually reducing. She continued to have intermittent polyarthritis with synovitis, but the disease became clinically inactive by November 1974. However, in April 1975, when she was taking...
prednisolone 10 mg daily, she complained of persistent pain in the left hip. Radiographs at that stage were normal but by October 1975 showed early changes and by January 1976 definite changes of osteonecrosis of the femoral head (Fig. 4). She was subsequently maintained on prednisolone 8 mg daily and the disease remained well controlled and the patient ambulant. In February 1977 she developed pain in the right shoulder, with limited movement; radiographs showed changes of osteonecrosis of the right humeral head (Fig. 5).

Case 6. A 16-year-old English girl presented in April 1973 with polyarthritis, the left wrist being most severely affected, facial rash, photosensitivity, and Raynaud’s phenomenon. LE cells and ANA were positive. Proteinuria was present, and renal biopsy showed an active, diffuse, proliferative glomerulonephritis. She was treated with prednisolone 40 mg daily, which was gradually reduced, and the disease became generally quiescent apart from persisting proteinuria. In December 1973 azathioprine 3 mg/kg body weight was introduced. In June 1975 she started work as a nurse, but in September 1975, when taking 15 mg prednisolone daily, she again complained of pain in the left wrist, with clinical evidence of synovitis. Radiographs then showed evidence of early osteonecrosis of the left lunate, which subsequently progressed (Fig. 6). The dose of prednisolone was gradually reduced to 10 mg daily, and the patient continued in full-time nursing.

Case 7. A 14-year-old Pakistani girl presented in April 1973 with facial rash, arthralgia and proteinuria. LE cells and ANA were positive. Haemoglobin electrophoresis was normal. She was treated with prednisolone, and this was increased to 100 mg daily in December 1973 because of the development of a nephrotic syndrome and worsening glomerular filtration rate (GFR). The disease gradually came into remission, but by June 1975 she started to complain of pain in both knees with swelling and synovitis. However, radiographs in June 1976 showed bilateral osteonecrosis of the lateral femoral condyles (Fig. 7). The disease was otherwise inactive apart from persisting proteinuria.

Case 8. A 46-year-old woman from Gibraltar presented with polyarthritis, psychosis, and pleurisy in 1964. LE cells and ANA were subsequently found to be positive, and she was treated with prednisolone 60 mg, reducing to 20 mg daily, which she took until August 1974. At that stage she was grossly cushingoid, but the disease was otherwise inactive apart from persistent pain in the right shoulder. Radiographs
showed the presence of osteonecrosis of the head of the right humerus (Fig. 8). Azathioprine 3 mg/kg body weight was added but had to be discontinued after 1 month because of leucopenia. Prednisolone dosage was reduced to 10 mg daily by June 1975, and the disease remained clinically inactive. In July 1975 she fell and sustained a fracture of the surgical neck of the left humerus, which had reunited without residual symptoms by November 1975, but in August 1976 she complained of pain in the left shoulder, with restricted movement, and X-ray evidence of osteonecrosis of the left humeral head was seen (Fig. 9). In February 1976 when taking prednisolone 6 mg daily, she complained of pain in
Clinical and radiological features of osteonecrosis in systemic lupus erythematosus

419

the left hip. Azathioprine 3 mg/kg body weight was reintroduced. Radiographs were normal at that stage but showed changes of osteonecrosis of the left femoral head by August 1976 (Fig. 10). The pain in the left hip became so troublesome that a total hip replacement was performed in February 1977, but the patient died suddenly of a pulmonary embolism on the 15th postoperative day.

When the maintenance dose of prednisolone prior to the onset of osteonecrosis was compared to the maintenance dose of prednisolone in patients without osteonecrosis statistically significant ($P<0.05$)

Fig. 10  Case 8. X-ray of left hip (a) 18 months before onset of pain and appearances, (b) 6 months, and (c) 12 months after onset of symptoms

![X-ray Images](image)

Fig. 11 a, b  Chronological relationship of disease activity and therapy to onset of osteonecrosis AN symptoms

![Graphs](image)
correlation was observed between higher prednisolone dosage in the osteonecrosis group (Table 2). However, 3 patients went on to develop osteonecrosis of further joints in spite of the prednisolone dose being lowered below 10 mg/day. No correlation was found between azathioprine or cyclophosphamide treatment and osteonecrosis.

Osteonecrosis tended to occur early in the disease, 7 patients developing it within 3 years of onset, and all patients had received relatively high doses of corticosteroids prior to the onset of symptoms (Fig. 11a, and b). However, the symptoms from osteonecrosis tended to occur when the disease had progressed from a clinically active phase into a stage of clinical quiescence. The serological changes at the onset of osteonecrosis symptoms also suggested that the disease was inactive. The complement level was normal in all the patients in whom it was measured and the DNA binding values were normal in 2 patients and only moderately raised in another 5 patients (Table 3).

The duration from the onset of symptoms which were subsequently referable to osteonecrosis to radiological changes in the affected joint are listed in Table 4. Four patients with osteonecrosis of weight-bearing joints had x-rays of the affected joints taken within 1 month of onset of symptoms, and although changes in the bone density were noted in some cases 5 to 7 months elapsed before radiological evidence of collapse of the articular surface occurred. However, in non-weight-bearing joints, typical x-ray changes with involvement of the articular surfaces were present with the onset of symptoms.

### Discussion

Osteonecrosis occurred in 12% of our SLE patients and indirectly led to the death of 1. In only 1 instance did an alternative explanation suggest itself, other than the underlying disease and its treatment, that being the osteonecrosis of the left head of humerus in case 8, which occurred 14 months after a fracture of the surgical neck of the left humerus. The incidence of osteonecrosis in our series is not dissimilar to that recently reported by Smith et al. (1976).

They observed symptomatic osteonecrosis in 7 out of 99 SLE patients; they also noticed a tendency for osteonecrosis to occur more commonly in the young patients and in those with leucopenia; neither of these associations were present in our population.

### Table 2 Maintenance dose of prednisone prior to osteonecrosis

<table>
<thead>
<tr>
<th>Prednisolone</th>
<th>SLE patients with osteonecrosis</th>
<th>SLE patients without osteonecrosis</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;10 mg/day</td>
<td>34†</td>
<td>1</td>
</tr>
<tr>
<td>&gt;10 mg/day</td>
<td>26</td>
<td>7</td>
</tr>
</tbody>
</table>

*P<0.05. 112 had never received corticosteroids.

### Table 3 Clinical and serological features of SLE patients with osteonecrosis

<table>
<thead>
<tr>
<th>Case</th>
<th>Age at onset SLE (years)</th>
<th>Sex</th>
<th>Duration of SLE prior to osteonecrosis (years)</th>
<th>Joints involved by osteonecrosis</th>
<th>Max. Pred. dose (mg/day)</th>
<th>Clinical status</th>
<th>DNA antibody level* units/ml</th>
<th>Total haemolytic complement level† (CH50)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>52</td>
<td>F</td>
<td>1</td>
<td>Hip</td>
<td>100</td>
<td>Quiescent</td>
<td>36</td>
<td>64</td>
</tr>
<tr>
<td>2</td>
<td>30</td>
<td>F</td>
<td>1½</td>
<td>Hip</td>
<td>40</td>
<td>Quiescent</td>
<td>66</td>
<td>62</td>
</tr>
<tr>
<td>3</td>
<td>19</td>
<td>F</td>
<td>2</td>
<td>Hip</td>
<td>60</td>
<td>Quiescent</td>
<td>66</td>
<td>62</td>
</tr>
<tr>
<td>4</td>
<td>28</td>
<td>F</td>
<td>2</td>
<td>Hip</td>
<td>100</td>
<td>Quiescent</td>
<td>49</td>
<td>44</td>
</tr>
<tr>
<td>5</td>
<td>25</td>
<td>F</td>
<td>2½</td>
<td>Hip and shoulder</td>
<td>60</td>
<td>Quiescent</td>
<td>18</td>
<td>51</td>
</tr>
<tr>
<td>6</td>
<td>16</td>
<td>F</td>
<td>2½</td>
<td>Lunate</td>
<td>40</td>
<td>Quiescent</td>
<td>31</td>
<td>40</td>
</tr>
<tr>
<td>7</td>
<td>14</td>
<td>F</td>
<td>2½</td>
<td>Both knees and elbow</td>
<td>100</td>
<td>Quiescent</td>
<td>16</td>
<td>68</td>
</tr>
<tr>
<td>8</td>
<td>46</td>
<td>F</td>
<td>10</td>
<td>Both shoulders hip and elbow</td>
<td>60</td>
<td>Quiescent</td>
<td>30</td>
<td>57</td>
</tr>
</tbody>
</table>

* DNA Ab—normal range = <25 units/ml. † CH50—normal range = 36–72 units/ml.
Bergstein et al. (1974) found a 40% incidence of radiological osteonecrosis in 35 children with SLE. In their 14 patients with radiological osteonecrosis a total of 31 sites were involved, but only 9 of these were symptomatic. All their patients appeared to have received prednisolone 2 mg/kg body weight. A high incidence of osteonecrosis among children with SLE was also reported by Hurley et al. (1974), who described symptomatic AN in 4 out of 10 patients.

Controversy concerning the role of corticosteroids in the aetiology of osteonecrosis in SLE exists. In the original description of Dubois and Cozens (1960) 5 of their 11 cases were not receiving corticosteroids at the time of the onset of osteonecrosis, and 1 of these had never received steroids. Osteonecrosis in 2 patients with discoid lupus erythematosus who were not receiving corticosteroids have also been recorded (Siemens et al., 1962; Leventhal and Dorffmann, 1974). However, most SLE patients with osteonecrosis are receiving corticosteroids (Leventhal and Dorffmann, 1974; Smith et al., 1976; Dubois, 1976) and all out patients were receiving steroids. The daily steroid dose in our series tended to be higher in the SLE patients with osteonecrosis than in those without. However, osteonecrosis progressed to involve further joints in 3 patients despite the steroid dosage being reduced.

Murray (1973) reviewed osteonecrosis following organ transplantation and found that the incidence fell from 34% to 10% when the mean dose of prednisolone given during the first 3 postoperative weeks was lowered from 2-9 g to 1-2 g. Osteonecrosis following high-dose corticosteroid therapy has also been reported in several conditions where primary abnormalities of bone are not suspected—pemphigus, erythema multiforme, multiple sclerosis, and thrombocytopenic purpura (Heinmann and Freiberger, 1960), and also in a patient with an adrenal adenoma (Madell and Freeman, 1964).

The relationship between underlying disease and corticosteroid therapy in the pathogenesis of osteonecrosis in SLE is made difficult because high doses of steroids tend to be reserved for patients with most active systemic disease. We, like Smith et al. (1976), were impressed by the tendency of osteonecrosis symptoms to occur when the disease had entered a clinically and serologically quiescent phase, usually after periods of active disease which had required high doses of steroids. It is possible that increased use of the joints during the remission may precipitate collapse of previously weakened bone.

The microscopic appearance of affected bone removed from SLE patients has not clearly shown the pathological process responsible for osteonecrosis. Leventhal and Dorffmann (1974) were unable to detect any histological evidence of vasculitis in the surgically removed osteonecrotic femoral head specimens from patients with SLE. However, the specimens were inevitably obtained some considerable time after the onset of clinical and radiological changes. In our series we failed to detect any serological abnormality usually associated with systemic vasculitis at the onset of symptoms, but this does not exclude the possibility that vasculitis predisposes to bone ischaemia, which subsequently fails to heal because of continued use of corticosteroids. Occlusive lesions of subchondral capillaries have been found in certain situations, such as rabbits treated with high doses of corticosteroids, where there is an increase in capillary fat globules (Jaffe et al., 1972; Fisher, 1978) and in sickle-cell disease (Tanaka et al., 1956) where it has been postulated that the increased blood viscosity associated with the higher haemoglobin levels may explain the increased incidence of osteonecrosis in the SC rather than SS haemoglobinopathies (Keeling et al., 1974). Attempts to show a reduction in blood flow to bones affected by osteonecrosis by means of 99Tc diphosphonate scintigraphy have been unsuccessful (D’Ambrosia et al., 1976), but prospective studies in high risk patients may reveal vascular changes prior to the onset of symptoms. At present the lack of confirmatory evidence that vascular occlusion is the cause of bone death in SLE caused us to prefer the term osteonecrosis to avascular necrosis.

Pain in weight-bearing joints frequently precedes radiological changes of osteonecrosis (Dubois, 1976), and in our series 5 to 7 months elapsed in some cases before radiological changes in the articular surfaces became apparent. A similar observation has also been made in patients with avascular necrosis associated with sickle-cell disease (Chung and Ralston, 1969). Sequential x-rays are required, therefore, if the diagnosis is not to be overlooked.

Weight-bearing joints are most commonly affected by osteonecrosis in SLE patients. In our series 7 of the 8 patients had disease of weight-bearing joints, and of the total of 13 joints involved 8 were weight-bearing. This picture is again similar to that seen in in sickle-cell disease (Tanaka et al., 1956) but strikingly dissimilar from the pattern of joint involvement seen in divers, in whom the humeral heads are more commonly affected than the femoral heads (Ohta and Matsunaga, 1974).

In 2 of our patients synovitis was observed at the site of subsequent osteonecrosis before the development of radiological changes. While the relevance of this is unknown, it can provide a diagnostic pitfall in that symptoms may be attributed purely to synovitis and an associated osteonecrosis over-
looked. The tendency for multiple joints to be involved may complicate management (Ruderman and McCart, 1964). Three of our patients had multiple joint involvement, and reducing the dose of corticosteroids seemed to be ineffective in halting the progression.

In our experience osteonecrosis tended to occur early in the disease and usually followed periods of active disease and aggressive corticosteroid therapy. We consider that the presence of persisting pain, particularly in a weight-bearing joint, in patients with SLE whose disease is otherwise quiescent, suggests that osteonecrosis is the most likely cause.

References


